EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 180

Inclusion Criteria

•Must have newly diagnosed CD20+ large cell lymphoma.
•Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy
due to:
oBeing age =80 years; AND/OR
oBeing age =75 years and having important comorbid condition(s),
which are likely to have a negative impact on tolerability of
anthracycline-based therapy/cytotoxic chemotherapy, Have Immune
Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of
10.
•Have Ann Arbor Stage II-IV disease.
•Have ECOG PS of 0, 1, or 2; (ECOG PS of 3 may be considered if
impairment is attributed to current lymphoma/DLBCL and if pre-phase
treatment during the screening phase results in an improvement of ECOG
PS to =2 prior to enrollment.)
•Have measurable disease as per Lugano criteria.
•Have acceptable organ function based on baseline bloodwork.
•Must have fresh (preferred) or archival biopsy material at screening.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 180

Exclusion Criteria

•Has known active, clinically significant bacterial, viral, fungal,
mycobacterial, parasitic, or other infection at trial enrollment, including
COVID-19 infection.
•Has severe cardiovascular disease (other than those eligibility criteria
that preclude the subject from receiving anthracycline-based
therapy/cytotoxic chemotherapy),
•Has been exposed to/received any of the following prior therapies,
treatments, or procedures within the specified timeframes:
oMajor surgery within 4 weeks prior to the first dose of epcoritamab;
oNon-investigational antineoplastic agents or any investigational drug
within 4 weeks or 5 half-lives, whichever is shorter, prior to the first
dose of epcoritamab;
oAutologous hematopoietic stem cell transplantation (HSCT), CAR-T,
allogeneic stem cell transplantation, or solid organ transplantation;
oLive, attenuated vaccines within 30 days prior to initiation of
epcoritamab;
oInvestigational vaccines within 28 days before the planned first dose of
epcoritamab (ie, experimental and/or non-authorized SARS-CoV-2
vaccinations and therapies are not allowed);
oInvasive investigational medical device use within 28 days before the
planned first dose of epcoritamab.
•Has primary central nervous system (CNS) tumor or known CNS
involvement or intracranial involvement as confirmed by mandatory
brain magnetic resonance imaging/computed tomography (MRI/CT)
scan at screening and, if clinically indicated, by lumbar puncture.
•Has a seizure disorder requiring anti-epileptic therapy or experienced a
seizure within 6 months of signing an informed consent form.
•Has known past or current malignancy other than inclusion diagnosis,
with exceptions as stated in protocol.
•Has known or suspected allergies, hypersensitivity, or intolerance to
either of the trial treatments or has known or suspected contraindication
to the use of all locally available anti-cytokine therapies per local
guidelines for management of cytokine release syndrome (CRS).
•Has active hepatitis B virus (HBV) (DNA polymerase chain reaction
[PCR]-positive) or hepatitis C virus (HCV) (RNA PCR-positive) infection,
current alcohol abuse, or cirrhosis.
•Has active cytomegalovirus (CMV) infection (DNA PCR-positive)
requiring treatment.
•Has suspected active or inadequately treated latent tuberculosis.
•Has a known history of seropositivity for HIV. Note: HIV testing is
required at screening only if required per local health authorities or
institutional standards.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials